These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2953934)

  • 1. Intensive short-term chemotherapy in patients with advanced breast cancer.
    Wander HE; Nagel GA; Luig H; Emrich D
    Klin Wochenschr; 1987 Apr; 65(7):317-23. PubMed ID: 2953934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
    Wander HE; Nagel GA; Blossey HC; Kleeberg U
    Cancer; 1986 Nov; 58(9):1985-9. PubMed ID: 2944573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE; Nagel GA; Blossey HC; Kordilla F; Stamm S; Matthressen W; Weiss J
    Onkologie; 1982 Aug; 5 Suppl():8-12. PubMed ID: 6752794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
    Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
    J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer].
    Aikawa T; Yayoi E; Takatsuka Y; Maeura Y; Miyauchi K
    Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Fluorouracil, adriamycin and cyclophosphamide combined with high-dose medroxyprogesterone acetate in advanced breast cancer.
    Lopez M; Di Lauro L; Perno CF; Papaldo P; Barduagni M; Barduagni A
    Tumori; 1983 Dec; 69(6):545-51. PubMed ID: 6229920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
    Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer.
    Fritze D; Queisser W; Schmid H; Kaufmann M; Massner B; Westerhausen M; Schmidt R; Edler L; Abel U
    Onkologie; 1986 Dec; 9(6):305-12. PubMed ID: 2950359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparative trial of combined versus alternating therapy with cytostatic drugs and high-dose medroxyprogesteron acetate in advanced breast cancer.
    Wils JA; Bron H; Van Lange L; Pannebakker M; Romme A; Scheerder H; Smeets JB; Beex LV
    Cancer; 1985 Sep; 56(6):1325-31. PubMed ID: 3896455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
    Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
    Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose epirubicin in combination with cyclophosphamide (HD-EC) in advanced breast cancer: final results of a dose finding study and phase II trial.
    Marschner N; Nagel GA; Beyer JH; Adler M; Ammon A
    Onkologie; 1990 Aug; 13(4):272-8. PubMed ID: 2234780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.